Novel Precision Medicine therapies, such as BRAF V600E inhibitors in patients with melanoma and PD1/PD-L1 immunotherapy for melanoma, lung, kidney, and other types of cancer [109,110], are enabling more efficient treatment with minimized side effects. This evidence concerns the gene BRAF and cancer.